Just three minor Form 483 observations followed a pre-approval inspection of New Jersey-based Catalent Pharma's integrated dose form development, manufacturing and packaging facility in Schorndorf, Germany. The facility provides formulation and development services as well as clinical and commercial manufacturing for oral tablets and capsules, powders and other dosage forms. Release